论文部分内容阅读
[目的]观察卵巢癌FIGO 2013新分期ⅠC期标准变化的合理性。[方法]选取113例ⅠC期卵巢癌病例,整理分析其术后病理资料和随访资料。将113例患者根据其病历资料按FIGO 2013新分期标准重新进行亚分期,分为ⅠC1、ⅠC2和ⅠC3期。从5年生存率及多因素分析两方面比较ⅠC期卵巢癌新分期变化的合理性。[结果]FIGO 1988年分期中ⅠC期卵巢癌5年生存率为82.4%;FIGO 2013年新分期中ⅠC1、ⅠC2和ⅠC3各亚期的5年生存率分别为92.1%、83.9%、79.5%,新分期各期的5年生存率差异无统计学意义(χ~2=2.881,P=0.237)。对肿瘤分期、年龄、初潮年龄、是否绝经、生育次数、病理学类型和组织学分级对预后的影响进行Cox回归分析,肿瘤分期、年龄、初潮年龄、是否绝经、生育次数、病理学类型并非影响预后的危险因素(P>0.05);而组织学分级是ⅠC期卵巢癌预后的危险因素(OR=1.474,P=0.001)。[结论]新分期将ⅠC期卵巢癌分为各亚期后其5年生存率无明显差异;ⅠC亚分期并不是影响卵巢癌预后的独立因素,组织学分级是卵巢癌预后的危险因素。因此FIGO2013将ⅠC期卵巢癌为ⅠC1、ⅠC2、ⅠC3亚期,似乎并不能更好地评估预后。
[Objective] To observe the rationality of Ⅰ C phase change in the new staging of ovarian cancer FIGO 2013. [Method] A total of 113 cases of stage ⅠC ovarian cancer were selected and their postoperative pathological data and follow-up data were analyzed. 113 patients were re-staged according to their medical records according to the new stage of FIGO 2013. They were divided into ⅠC1, ⅠC2 and ⅠC3. From the 5-year survival rate and multivariate analysis of two aspects of Ⅰ C stage ovarian cancer staging of changes in the rationality. [Results] The 5-year survival rate of FIGO in the staging of 1988 stage was 82.4%. The 5-year survival rates of the FIGO stage in the new stage of FIGO in 2013 were 92.1%, 83.9% and 79.5% respectively, There was no significant difference in 5-year survival rates between the new staging stages (χ ~ 2 = 2.881, P = 0.237). Cox regression analysis was performed on the effect of tumor stage, age, age of menarche, menopause, number of births, pathological types and histological grade on prognosis. There was no significant difference in tumor stage, age, age of menarche, menopause, number of births and pathological types (P> 0.05). The histological grade was the risk factor of prognosis in stage ⅠC ovarian cancer (OR = 1.474, P = 0.001). [Conclusion] There is no significant difference in the 5-year survival rate of the stage ⅠC ovarian cancer among the new staging stages. The subclassification of stage ⅠC is not an independent factor affecting the prognosis of ovarian cancer. The histological grade is the risk factor for the prognosis of ovarian cancer. So FIGO2013 Ⅰ C stage ovarian cancer as Ⅰ C1, Ⅰ C2, Ⅰ C3 sub-phase, does not seem to be able to better assess the prognosis.